<DOC>
	<DOCNO>NCT02743806</DOCNO>
	<brief_summary>The purpose study monitor ongoing safety subject ulcerative colitis ( UC ) Crohn 's disease ( CD ) provide access vedolizumab qualify subject , opinion investigator , continue derive benefit vedolizumab continue treatment vedolizumab desire comparable product available subject may expect develop worsen disease modify treatment .</brief_summary>
	<brief_title>Extended Access Program Vedolizumab IV Ulcerative Colitis Crohn 's Disease</brief_title>
	<detailed_description>The drug use study call vedolizumab , use treat people ulcerative colitis Crohn 's disease . This study monitor ongoing safety people take vedolizumab . Participants successfully complete participation qualify vedolizumab clinical study enrol assigned receive : â€¢ Vedolizumab 300 mg All participant receive intravenous infusion every 8 week vedolizumab available commercial channel , include reimbursement , participant 's clinical scenario , participant withdrawal , whichever come first . ( Per MM approval , dose regiman may modify ) This multicenter trial conduct worldwide . Participants make multiple visit clinic final visit 18 week receive last dose study infusion vedolizumab safety follow-up assessment .</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<mesh_term>Vedolizumab</mesh_term>
	<criteria>1 . Received vedolizumab ( exclude comparator placebo participant ) participation qualify vedolizumab study . 2 . In opinion investigator , participant continue derive benefit vedolizumab continue treatment vedolizumab desire comparable product available participant may expect develop worsen disease modify treatment . 3 . A male participant nonsterilized sexually active female partner childbearing potential agrees use adequate contraception signing inform consent throughout duration study 18 week last dose . 4 . A female participant childbearing potential sexually active nonsterilized male partner agree use routinely adequate contraception signing inform consent throughout duration study 18 week last dose . 1 . For participant 's particular clinical scenario , vedolizumab currently available participant commercial channel , include reimbursement . 2 . Has clinical condition prior therapy , opinion investigator , would make participant unsuitable study unable comply dose requirement pose risk participant study . 3 . If female , participant pregnant lactate intend become pregnant , , within 18 week participate study ; intend donate ova time period . 4 . If male , participant intend donate sperm course study 18 week thereafter . 5 . Has receive live vaccine last 18 week need live vaccine study 18 week last study dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>